Vaxxas Publication in PLoS Medicine Reveals Groundbreaking Clinical Research on Broad Potential of Novel High-Density Microarray Patch (HD-MAP)

To Effeciently Deliver Vaccines Directly to the Skin, Enhancing Immunogenicity

Read the full media release below.

Learn more

Posted in — Media Release


You may also like

22 July 2020

OneVentures Venture Credit Fund poised to invest $120M into Australian scaleups

05 August 2018

Australian First:-Israeli venture partnership launches new Venture Credit Fund to invest in high-growth technology companies

18 July 2016

DoseMe partners with Charm Health to improve management of high risk oncology medicines and deliver “precision medicine” to Australian cancer patients

19 May 2020

OneVentures expands team to internationalise its healthcare portfolio

17 December 2015

OneVentures’ Innovation and Growth Fund II hits $100 million in FUM

04 September 2017

Citadel Group aquires OneVentures portfolio company Charm Health

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor